← All trials
NCT05523596
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Dec 31, 2026
- Completion date
- Mar 31, 2027
- First posted
- Aug 31, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IC-MedTech CorporationLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.